• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

白细胞介素6非依赖型多发性骨髓瘤细胞中丝裂原活化蛋白激酶级联信号通路的阻断

Blockade of mitogen-activated protein kinase cascade signaling in interleukin 6-independent multiple myeloma cells.

作者信息

Ogata A, Chauhan D, Urashima M, Teoh G, Treon S P, Anderson K C

机构信息

Division of Hematologic Malignancies, Dana-Farber Cancer Institute, and Department of Medicine, Harvard Medical School, Boston, Massachusetts 02215, USA.

出版信息

Clin Cancer Res. 1997 Jun;3(6):1017-22.

PMID:9815779
Abstract

Interleukin 6 (IL-6) is a growth factor for multiple myeloma (MM) cells, yet not all MM cell lines or patient cells require IL-6 for their growth. It is well known that IL-6 activates the signal transducers and activators of transcription (stat) 1-stat3 heterodimer, stat3 homodimer, and Ras-dependent mitogen-activated protein kinase (MAPK) cascades in multiple cell systems. We have shown previously that the MAPK pathway is an important pathway for IL-6-mediated MM cell growth. In this study, we delineate the pattern of upstream MAPK cascade activation in IL-6-responsive B9 cells and in IL-6-nonresponsive U266, OCI-My5, and RPMI8226 MM cells to define sites of blockade of this pathway associated with loss of responsiveness to IL-6. In B9 cells, IL-6 triggered the following in sequence: gp130 phosphorylation, gp130-to-protein tyrosine phosphatase 1D (PTP1D) binding, PTP1D phosphorylation, PTP1D complex formation with Grb2-Son of sevenless 1 (Sos1), and Sos1 phosphorylation. gp130 phosphorylation, gp130-to-PTP1D binding, PTP1D phosphorylation, and PTP1D-to-Grb2 binding are also induced by IL-6 in all IL-6-independent MM cell lines studied. However, Grb2 is not associated with Sos1, and neither Grb2-to-Sos1 binding nor Sos1 phosphorylation is triggered by IL-6 in OCI-My5 MM cells. On the other hand, Grb2 and Sos1 are associated constitutively in U266 and RPMI8226 MM cells, but phosphorylation of Sos1 is not induced by IL-6. These data suggest that lack of Sos1 activation is associated with loss of IL-6 responsiveness in MM cell lines that grow independently of IL-6.

摘要

白细胞介素6(IL-6)是多发性骨髓瘤(MM)细胞的生长因子,但并非所有MM细胞系或患者细胞的生长都需要IL-6。众所周知,IL-6在多种细胞系统中可激活信号转导子和转录激活子(STAT)1-STAT3异二聚体、STAT3同二聚体以及Ras依赖性丝裂原活化蛋白激酶(MAPK)级联反应。我们之前已经表明,MAPK途径是IL-6介导的MM细胞生长的重要途径。在本研究中,我们描绘了IL-6反应性B9细胞以及IL-6无反应性U266、OCI-My5和RPMI8226 MM细胞中上游MAPK级联反应激活的模式,以确定该途径中与对IL-6反应性丧失相关的阻断位点。在B9细胞中,IL-6依次引发以下反应:gp130磷酸化、gp130与蛋白酪氨酸磷酸酶1D(PTP1D)结合、PTP1D磷酸化、PTP1D与Grb2-七号less之子1(Sos1)形成复合物以及Sos1磷酸化。在所研究的所有不依赖IL-6的MM细胞系中,IL-6也可诱导gp130磷酸化、gp130与PTP1D结合、PTP1D磷酸化以及PTP1D与Grb2结合。然而,在OCI-My5 MM细胞中,Grb2不与Sos1结合,IL-6也不会引发Grb2与Sos1结合或Sos1磷酸化。另一方面,在U266和RPMI8226 MM细胞中,Grb2和Sos1组成性结合,但IL-6不会诱导Sos1磷酸化。这些数据表明,在不依赖IL-6生长的MM细胞系中,Sos1激活的缺失与IL-6反应性的丧失有关。

相似文献

1
Blockade of mitogen-activated protein kinase cascade signaling in interleukin 6-independent multiple myeloma cells.白细胞介素6非依赖型多发性骨髓瘤细胞中丝裂原活化蛋白激酶级联信号通路的阻断
Clin Cancer Res. 1997 Jun;3(6):1017-22.
2
Grb2 regulates Stat3 activation negatively in epidermal growth factor signalling.Grb2在表皮生长因子信号传导中对Stat3激活起负向调节作用。
Biochem J. 2003 Dec 1;376(Pt 2):457-64. doi: 10.1042/BJ20030668.
3
IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade.白细胞介素-6通过依赖Ras的丝裂原活化蛋白激酶级联反应触发细胞生长。
J Immunol. 1997 Sep 1;159(5):2212-21.
4
Sos1 rapidly associates with Grb2 and is hypophosphorylated when complexed with the EGF receptor after EGF stimulation.在表皮生长因子(EGF)刺激后,Sos1迅速与Grb2结合,并且在与EGF受体复合时发生低磷酸化。
Oncogene. 1996 May 2;12(9):1865-72.
5
Specific inhibition of FGF-induced MAPK activation by the receptor-like protein tyrosine phosphatase LAR.受体样蛋白酪氨酸磷酸酶LAR对成纤维细胞生长因子诱导的丝裂原活化蛋白激酶激活的特异性抑制作用。
Oncogene. 2000 May 4;19(19):2346-53. doi: 10.1038/sj.onc.1203558.
6
Involvement of tyrosine phosphatase PTP1D in the inhibition of interleukin-6-induced Stat3 signaling by alpha-thrombin.酪氨酸磷酸酶PTP1D参与α-凝血酶对白细胞介素-6诱导的Stat3信号传导的抑制作用。
Biochem Biophys Res Commun. 2001 Oct 19;288(1):252-7. doi: 10.1006/bbrc.2001.5759.
7
Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma.蛋白酶体抑制剂PS-341通过半胱天冬酶依赖性下调多发性骨髓瘤中的gp130消除白细胞介素-6触发的信号级联反应。
Oncogene. 2003 Nov 20;22(52):8386-93. doi: 10.1038/sj.onc.1207170.
8
Physician Education: The Erythropoietin Receptor and Signal Transduction.医师教育:促红细胞生成素受体与信号转导
Oncologist. 1996;1(5):337-339.
9
p21Ras activation by the guanine nucleotide exchange factor Sos, requires the Sos/Grb2 interaction and a second ligand-dependent signal involving the Sos N-terminus.鸟嘌呤核苷酸交换因子Sos对p21Ras的激活需要Sos/Grb2相互作用以及涉及Sos N端的第二个配体依赖性信号。
Oncogene. 1996 Nov 21;13(10):2055-65.
10
IL-6-gp130-STAT3 in T cells directs the development of IL-17+ Th with a minimum effect on that of Treg in the steady state.T细胞中的白细胞介素-6-糖蛋白130-信号转导子和转录激活子3在稳态下指导白细胞介素-17⁺辅助性T细胞的发育,对调节性T细胞的发育影响最小。
Int Immunol. 2007 Jun;19(6):695-702. doi: 10.1093/intimm/dxm045. Epub 2007 May 9.

引用本文的文献

1
Cell-based screen identifies porphyrins as FGFR3 activity inhibitors with therapeutic potential for achondroplasia and cancer.基于细胞的筛选鉴定出卟啉类化合物为成纤维细胞生长因子受体 3(FGFR3)活性抑制剂,具有治疗软骨发育不全症和癌症的潜力。
JCI Insight. 2023 Nov 22;8(22):e171257. doi: 10.1172/jci.insight.171257.
2
Signaling Pathway Mediating Myeloma Cell Growth and Survival.介导骨髓瘤细胞生长与存活的信号通路
Cancers (Basel). 2021 Jan 8;13(2):216. doi: 10.3390/cancers13020216.
3
The novel JAK inhibitor AZD1480 blocks STAT3 and FGFR3 signaling, resulting in suppression of human myeloma cell growth and survival.
新型 JAK 抑制剂 AZD1480 可阻断 STAT3 和 FGFR3 信号通路,从而抑制人骨髓瘤细胞的生长和存活。
Leukemia. 2011 Mar;25(3):538-50. doi: 10.1038/leu.2010.289. Epub 2010 Dec 17.
4
In vitro cytotoxicity of the novel antimyeloma agents perifosine, bortezomib and lenalidomide against different cell lines.新型骨髓瘤药物培非司亭、硼替佐米和来那度胺对不同细胞系的体外细胞毒性。
Invest New Drugs. 2012 Apr;30(2):480-9. doi: 10.1007/s10637-010-9576-2. Epub 2010 Nov 16.
5
Differential activities of thalidomide and isoprenoid biosynthetic pathway inhibitors in multiple myeloma cells.沙利度胺和异戊烯生物合成途径抑制剂在多发性骨髓瘤细胞中的差异活性。
Leuk Res. 2010 Mar;34(3):344-51. doi: 10.1016/j.leukres.2009.06.035. Epub 2009 Jul 30.
6
SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK.SNX-2112是一种选择性热休克蛋白90(Hsp90)抑制剂,通过消除Akt和ERK信号传导,有效抑制多发性骨髓瘤和其他血液肿瘤中的肿瘤细胞生长、血管生成和破骨细胞生成。
Blood. 2009 Jan 22;113(4):846-55. doi: 10.1182/blood-2008-04-151928. Epub 2008 Oct 23.
7
Therapeutic effects of thalidomide in myeloma are associated with the expression of fibroblast growth factor receptor 3.沙利度胺治疗骨髓瘤的疗效与成纤维细胞生长因子受体 3 的表达有关。
Ther Clin Risk Manag. 2005 Sep;1(3):231-41.
8
Preclinical studies of novel targeted therapies.新型靶向治疗的临床前研究。
Hematol Oncol Clin North Am. 2007 Dec;21(6):1071-91, viii-ix. doi: 10.1016/j.hoc.2007.08.013.
9
New frontiers in the treatment of multiple myeloma.多发性骨髓瘤治疗的新前沿
ScientificWorldJournal. 2006 Dec 6;6:1475-503. doi: 10.1100/tsw.2006.236.
10
Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells.哌立福新是一种具有口服生物活性的新型烷基磷脂,它可抑制Akt,并在体外和体内诱导人多发性骨髓瘤细胞产生细胞毒性。
Blood. 2006 May 15;107(10):4053-62. doi: 10.1182/blood-2005-08-3434. Epub 2006 Jan 17.